BLISS GVS PHARMA LTD. Q1 FY27 Results

Bliss GVS Pharma's consolidated (primary basis) revenue for Q1 FY27 came in at ₹285.58 Cr, up 37.6% YoY from ₹207.47 Cr and up 11.1% QoQ from ₹256.99 Cr in Q4 FY26. Consolidated PAT was ₹51.37 Cr, up 15.8% YoY from ₹44.36 Cr and up 38.8% QoQ from ₹37.00 Cr; consolidated basic EPS was ₹4.73 versus ₹4.08 a year ago and ₹3.37 last quarter. No street/consensus estimates for this print could be located (a small-cap with thin analyst coverage), and management has no formal guidance on record, so vsGuidance and vsStreet are both unknown.

The headline PAT growth understates the operating performance. Operating margin (profit before exceptional items, tax and other income, adjusted for finance cost and depreciation, over revenue) expanded to 26.8% from 19.9% YoY and 17.3% QoQ, driven by materials-cost efficiency — cost of materials consumed fell to 33.1% of revenue from 45.0% a year ago. The reason reported consolidated PAT growth (15.8%) trails both revenue growth (37.6%) and the operating margin gain is a high year-ago other-income base: consolidated other income was ₹9.60 Cr this quarter versus ₹35.45 Cr in Q1 FY26 (-72.9%), almost entirely a consolidation/subsidiary-level item — standalone other income fell only 17.3% YoY (₹10.59 Cr to ₹8.76 Cr), while the consolidation-only portion collapsed from roughly ₹24.86 Cr to ₹0.84 Cr. Neither quarter carries a company-flagged exceptional item, so this reads as a genuine other-income base effect rather than a disclosed one-off.

The stock went into the print at ₹527.1, up 21.3% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

On a standalone (parent-only) basis, PAT surged 83.4% YoY to ₹38.62 Cr on 35.6% revenue growth to ₹221.59 Cr — far outpacing the consolidated print — because subsidiary/overseas profit contribution nearly halved YoY (from roughly ₹23.31 Cr to ₹12.75 Cr), consistent with the other-income swing above; readers comparing the two bases should not read the gap as a standalone-vs-consolidated conflict on operations, just the other-income base effect flowing through the subsidiaries. Finance costs also fell sharply on both bases (consolidated ₹0.58 Cr vs ₹5.47 Cr YoY, -89%; standalone ₹0.39 Cr vs ₹5.11 Cr, -92%), consistent with debt reduction and a further, smaller tailwind to profitability. Separately, the quarter saw an active shareholding contest unrelated to the operating print: Anupam Rasayan launched a ₹299/share open offer for the company on July 21, 2026 (PAC added July 19), Clarus Capital I disclosed a 5.13% stake on July 22, and LIC disclosed a 5.11% stake on August 11. No management press release accompanying this result was available to cross-check against the numbers.